As new drug launches approach, the public will gain insights into the pricing of medications under President Trump's most-favored-nation agreements with 17 pharmaceutical companies. These deals mandate that new drugs be introduced in the U.S. at net prices comparable to those in other affluent nations, though specific terms remain undisclosed. The upcoming launches include Baxfendy, a hypertension treatment from AstraZeneca, Awiqli, an insulin product from Novo Nordisk, and Veppanu, a cancer therapy developed by Arvinas and Pfizer, which will be licensed to Rigel Pharmaceuticals. Notably, Baxfendy and Veppanu are not yet available in the countries used for pricing comparisons. This situation presents a critical opportunity to evaluate the effectiveness and impact of Trump's drug pricing initiatives on the U.S. pharmaceutical market, as these drugs will serve as the first real-world examples of the pricing strategies resulting from these agreements.